ABBV
Price
$284.94
Change
+$0.14 (+0.05%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
503.27B
8 days until earnings call
Intraday BUY SELL Signals
NSRX
Price
$3.49
Change
+$0.43 (+14.05%)
Updated
Oct 22, 04:58 PM (EDT)
Capitalization
35.84M
41 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ABBV vs NSRX

ABBV vs NSRX Comparison Chart in %
View a ticker or compare two or three
VS
ABBV vs. NSRX commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a Buy and NSRX is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ABBV with price predictions
Oct 22, 2026

ABBV's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for ABBV turned positive on October 07, 2026. Looking at past instances where ABBV's MACD turned positive, the stock continued to rise in 34 of 46 cases over the following month. The odds of a continued upward trend are 74%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on ABBV as a result. In 52 of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.

Following a +1.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABBV advanced for three days, in 220 of 361 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.

The Aroon Indicator entered an Uptrend today. In 224 of 356 cases where ABBV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 63%.

Bearish Trend Analysis

The 10-day RSI Indicator for ABBV moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 46 similar instances where the indicator moved out of overbought territory. In 19 of the 46 cases, the stock moved lower in the following days. This puts the odds of a move lower at 41%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABBV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 46%.

ABBV broke above its upper Bollinger Band on October 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 1 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (-84.798) is very low in comparison to the industry average of (-3.019). ABBV has a moderately high P/E Ratio (80.452) as compared to the industry average of (21.251). Projected Growth (PEG Ratio) (0.544) is also within normal values, averaging (5.738). Dividend Yield (0.024) settles around the average of (0.041) among similar stocks. ABBV's P/S Ratio (7.231) is slightly higher than the industry average of (4.033).

The Tickeron Profit vs. Risk Rating rating for this company is 3 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 12 (best 1 - 100 worst), indicating outstanding price growth. ABBV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
a Summary for NSRX with price predictions
Oct 22, 2026

NSRX's RSI Indicator ascending out of oversold territory

The RSI Oscillator for NSRX moved out of oversold territory on October 22, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 5 similar instances when the indicator left oversold territory. In 5 of the 5 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where NSRX advanced for three days, in 36 of 44 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

NSRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 34 of 36 cases where NSRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NSRX as a result. In 21 of 23 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for NSRX turned negative on October 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 12 similar instances when the indicator turned negative. In 12 of the 12 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

NSRX moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for NSRX crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 3 of 3 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NSRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.260) is normal, around the industry mean (-3.019). P/E Ratio (-2.728) is within average values for comparable stocks, (21.251). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.738). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. NSRX's P/S Ratio (0.000) is slightly lower than the industry average of (4.033).

The Tickeron PE Growth Rating for this company is 43 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. NSRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NSRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.

FUNDAMENTALS RATINGS
ABBV: Fundamental Ratings
ABBV
OUTLOOK RATING
1..100
43
VALUATION
overvalued / fair valued / undervalued
1..100
3
Undervalued
PROFIT vs RISK RATING
1..100
3
SMR RATING
1..100
1
PRICE GROWTH RATING
1..100
12
P/E GROWTH RATING
1..100
74
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ABBVNSRX
RSI
ODDS (%)
Bearish Trend 1 day ago
41%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
40%
Bullish Trend 1 day ago
81%
Momentum
ODDS (%)
Bullish Trend 1 day ago
68%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
63%
Bullish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
64%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 7 days ago
61%
Bullish Trend 3 days ago
82%
Declines
ODDS (%)
Bearish Trend 22 days ago
46%
Bearish Trend 10 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
40%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
63%
Bullish Trend 1 day ago
90%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (ABBV: $284.80 vs. NSRX: $3.06)
Brand notoriety: ABBV: Notable vs. NSRX: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: ABBV: 97% vs. NSRX: 243%
Market capitalization -- ABBV: $503.27B vs. NSRX: $35.84M
ABBV [@Pharmaceuticals: Major] is valued at $503.27B. NSRX’s [@Pharmaceuticals: Major] market capitalization is $35.84M. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $4.8K to $1.13T. The average market capitalization across the [@Pharmaceuticals: Major] industry is $206.81B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABBV’s FA Score shows that 4 FA rating(s) are green while NSRX’s FA Score has 0 green FA rating(s).

  • ABBV’s FA Score: 4 green, 1 red.
  • NSRX’s FA Score: 0 green, 5 red.
According to our system of comparison, ABBV is a better buy in the long-term than NSRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABBV’s TA Score shows that 4 TA indicator(s) are bullish while NSRX’s TA Score has 5 bullish TA indicator(s).

  • ABBV’s TA Score: 4 bullish, 4 bearish.
  • NSRX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ABBV is a better buy in the short-term than NSRX.

Price Growth

ABBV (@Pharmaceuticals: Major) experienced а +1.08% price change this week, while NSRX (@Pharmaceuticals: Major) price change was -3.77% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.73%. For the same industry, the average monthly price growth was -4.97%, and the average quarterly price growth was +5.45%.

Reported Earning Dates

ABBV is expected to report earnings on Oct 30, 2026.

NSRX is expected to report earnings on Dec 02, 2026.

Industries' Descriptions

@Pharmaceuticals: Major (+0.73% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

View a ticker or compare two or three
ABBV
Daily Signal:
Gain/Loss:
NSRX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

ABBV and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with NVS. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then NVS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABBV
1D Price
Change %
ABBV100%
+0.14%
NVS - ABBV
50%
Loosely correlated
+1.52%
JNJ - ABBV
49%
Loosely correlated
+3.81%
AMGN - ABBV
48%
Loosely correlated
+2.04%
BMY - ABBV
47%
Loosely correlated
+3.08%
BIIB - ABBV
41%
Loosely correlated
+5.34%
More

NSRX and

Correlation & Price change

A.I.dvisor tells us that NSRX and MDCX have been poorly correlated (+3% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NSRX and MDCX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NSRX
1D Price
Change %
NSRX100%
+5.56%
MDCX - NSRX
3%
Poorly correlated
-2.24%
OGN - NSRX
-3%
Poorly correlated
N/A
ABBV - NSRX
-7%
Poorly correlated
+0.14%
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ESQ123.194.47
+3.77%
Esquire Financial Holdings
NODK14.920.30
+2.05%
NI Holdings
DE643.627.08
+1.11%
Deere & Company
LNTH100.10-0.14
-0.14%
Lantheus Holdings
EYPT0.43N/A
-0.44%
EyePoint Inc.